In episode 418, Tina, Mike and James continue to talk about managing opioid use disorder in primary care. We talk about tools used for case finding and decide the POMI tool is the most useful. We also discuss whether or not tapering is useful and look at the naltrexone data.

Show notes

In episode 417, Mike and James invite Tina Korownyk to talk about all the work our PEER group did in developing a simplified guideline for managing opioid use disorder in primary care.

In episode 416, James and Mike talk about the recently released CABANA study, the largest and longest trial done on catheter ablation for symptomatic atrial fibrillation. We find that in general the ablation group had fewer negative clinical outcomes and an improved quality of life.

In episode 415, Mike and James continue with an overview of the evidence around depression. In this episode we talk about the use of antipsychotics for depression or augmentation of antidepressants, stopping antidepressants and the chances of withdrawal, and non-medication treatments.

Show notes

In episode 414, Mike and James continue with an overview of the evidence around depression. In this episode we talk about antidepressant management nuances from lower doses, to dose escalation, switching, and the time to response.

Show notes

Handout

In episode 413, Mike and James continue with an overview of the evidence around depression. In this episode we talk about the evidence around the effectiveness of antidepressants and learn if they work, how well they work, and if any one is better than the others.

Show notes

Handout

In episode 412, Mike and James do an overview of the evidence around depression. In this episode we talk about ruling out depression and the struggle of how to look at antidepressant evidence.

Show notes

Handout

In episode 411, Mike and James get annoyed – obviously in a nice way - having to talk about a new cohort study on eggs and an RCT of yet another omega-3 product. We try to put them into the context of all the other evidence available for these “products”.

Show notes